At a glance
ClinicalIndex Comparison Record- ✓Age >18 years
- ✓History of heartburn at least 2 days per week over the past month
- ✓If female and of childbearing potential, using an approved method of contraception since last menstrual period and negative serum pregnancy test
- ✕History of erosive esophagitis verified by endoscopy
- ✕History of GERD diagnosed by a physician
- ✕History of Barrett's esophagus or esophageal stricture
- ✕Any medical condition that may interfere with study conduct or patient health
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
In Brief
A Phase 3 clinical trial evaluating rabeprazole sodium and Placebo for Heartburn. Completed, enrolled 629 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the safety and efficacy of rabeprazole sodium 10 mg in treating frequent heartburn.
Study Details
Timeline
Interventions
Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.